This work was partially supported by grants from the National Natural Science Foundation of China(Nos.31971302 and 82170532);the Natural Science Foundation of Guangdong Province of China(No.2019A1515011597);the talent young scientist supporting program of China Association for Science and Technology,the Educational Commission of Guangdong Province of China key Project(No.2020ZDZX2001);the joint grant between Guangzhou City and College(No.202102010106);Guangzhou Science and Technology Plan Project(No.202201011509).
Patients with ulcerative colitis(UC)often loss responses over long term usage of conventional therapies.Tofacitinib,a pan-Janus kinases(JAK)inhibitor is approved for moderate to severe UC treatment,while dose-limiting...